Table 1.

Key Characteristics of Placebo‐Controlled Trials

	RADIANCE‐HTN SOLO (2018)	RADIANCE‐HTN TRIO (2021)	SPYRAL HTN‐OFF MED Pivotal (2020)	SPYRAL HTN‐ON MED (2018)	MODERATO II (2021)
Mean age, y	54	53	53	53	74
Women, %	42	20	34	16	36
Number of antihypertensive drugs (inclusion criterion)	0	3	0	1–3	≥1
Mean number of antihypertensive drugs at randomization	0	3	0	2.2	3.3
BP inclusion criterion, mm Hg	Daytime ambulatory BP: 135–164/85–104	Daytime ambulatory SBP: ≥135/85	24 h‐SBP: 140–169 OBP: 150–179/≥90	24 h‐SBP: 140–169 OBP: 150–179/≥90	Daytime SBP: ≥130 (≥125 after run‐in) Office SBP ≥140
Mean office SBP at baseline, mm Hg	154	155	163	164	154
Mean office DBP at baseline, mm Hg	100	100	101	101	82
Mean 24‐h SBP at baseline, mm Hg	150	144	151	152	136
Mean 24‐h DBP at baseline, mm Hg	93	89	99	97	73
Follow‐up duration, mo	2	2	3	6	6

BP indicates blood pressure; DBP, diastolic blood pressure; OBP, office blood pressure; and SBP, systolic blood pressure.